¾ËÄÚ¿Ã »ç¿ë Àå¾Ö ȯÀÚ¿¡¼­ µ¿¹ÝµÇ´Â º£¸£´ÏÄÉ ³úº´ÁõÀÇ ¼±º°°Ë»ç·Î¼­Æ¼¾Æ¹Î Ç÷Áß³óµµÀÇ Áø´ÜÀû À¯¿ë¼º
Diagnostic Usefulness of Blood Thiamine Levels as Screening Tests for Wernicke's Encephalopathy in Patients with Alcohol Use Disorder

Áßµ¶Á¤½ÅÀÇÇÐ 2017³â 21±Ç 1È£ p.17 ~ p.21

ÃÖµ¿·Ä(Choi Dong-Ryeol) - ¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ Á¤½Å°Ç°­ÀÇÇб³½Ç
Á¤¿µÃ¶(Jung Young-Chul) - ¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ Á¤½Å°Ç°­ÀÇÇб³½Ç

Abstract

Objectives : The purpose of this study was to evaluate the utility in measuring the blood thiamine and thiamine pyrophosphate (TPP) levels as screening tests for Wernicke encephalopathy in patients with alcohol use disorder.

Methods : We analyzed the demographic, clinical and laboratory data from 35 patients with alcohol use disorder. The blood thiamine and TPP levels were acquired at admission prior to initiation of thiamine intravenous (IV) therapy. We examined whether the blood thiamine and TPP levels correlated with clinical symptoms by applying the Caine's criteria. Patients who met at least one of Caine's criteria were considered at high risk for Wernicke encephalopathy and were treated with high-dose thiamine IV therapy.

Results : There was no correlation between blood thiamine/TPP levels and clinical symptoms of Wernicke encephalopathy. Clinical manifestations of the below-normal TPP-level group were not different from the normal TPP-level group, except that the normal TPP-level group showed a higher revised clinical institute withdrawal assessment for alcohol (CIWA) scores.

Conclusion : Measuring blood thiamine/TPP levels was not sensitive as screening tests for Wernicke encephalopathy among patients with alcohol use disorder. High-dose thiamine IV therapy improved the clinical symptoms of Wernicke encephalopathy in patients with alcohol use disorder.

Å°¿öµå

º£¸£´ÏÄÉ ³úº´Áõ, Ƽ¾Æ¹Î, Ƽ¾Æ¹Î ÇÇ·ÎÀλ꿰 ³óµµ, ÄÉÀÎÀÇ ±âÁØ
Wernicke encephalopathy, Thiamine, Thiamine pyrophosphate level, Caine's criteria
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
ÇмúÁøÈïÀç´Ü(KCI) 
ÁÖÁ¦ÄÚµå
ÁÖÁ¦¸í(Target field)
¿¬±¸´ë»ó(Population)
¿¬±¸Âü¿©(Sample size)
´ë»ó¼ºº°(Gender)
Áúº´Æ¯¼º(Condition Category)
¿¬±¸È¯°æ(Setting)
¿¬±¸¼³°è(Study Design)
¿¬±¸±â°£(Period)
ÁßÀç¹æ¹ý(Intervention Type)
ÁßÀç¸íĪ(Intervention Name)
Å°¿öµå(Keyword)
À¯È¿¼º°á°ú(Recomendation)
Measuring blood thiamine/TPP levels was not sensitive as screening tests for Wernicke encephalopathy among patients with alcohol use disorder.
¿¬±¸ºñÁö¿ø(Fund Source)
±Ù°Å¼öÁØÆò°¡(Evidence Hierarchy)
ÃâÆdz⵵(Year)
Âü¿©ÀúÀÚ¼ö(Authors)
´ëÇ¥ÀúÀÚ
DOI
KCDÄÚµå
ICD 03
°Ç°­º¸ÇèÄÚµå